Form 4: Aadi Bioscience Director Karin M. Hehenberger Acquires Stock Options

Director Karin M. Hehenberger acquired stock options in Aadi Bioscience, Inc. on June 12, 2024.

Summary

• Karin M. Hehenberger, a director of Aadi Bioscience, Inc., acquired stock options on June 12, 2024.
• The stock options grant the right to buy 45,832 shares of common stock at an exercise price of $1.70.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service as a Service Provider.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director is generally viewed as a mildly positive signal.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the reporting person's continued service to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, although some companies may use different vesting periods or performance-based vesting criteria.
• Comparing the size of the grant (45,832 shares) to similar companies would require analyzing their executive compensation disclosures.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates